Aethlon Medical INC 8-K filings

Aethlon Medical announced its fiscal year 2024 financial results and provided an update on the progress of its Hemopurifier device, including ethics approval for a cancer trial in Australia.

Aethlon Medical, Inc. reports 9,229,725 outstanding shares following a recent best-efforts public offering.

Aethlon Medical has announced the pricing of a public offering to raise approximately $4.7 million through the sale of common stock, pre-funded warrants, and accompanying Class A and Class B warrants.

Aethlon Medical reports successful in vitro binding study results showing its Hemopurifier device can remove extracellular vesicles from cancer patient plasma, supporting planned Phase 1 clinical trials.

Aethlon Medical's corporate presentation details the potential of its Hemopurifier device in treating cancer, viral infections, and improving organ transplantation outcomes.

Aethlon Medical announced its fiscal third quarter results, highlighting progress in its Hemopurifier development and clinical trials, while also reporting increased operating expenses and net loss.